GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » Beta

Solvonis Therapeutics (LSE:SVNS) Beta : 1.67 (As of Mar. 22, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Solvonis Therapeutics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2025-03-22), Solvonis Therapeutics's Beta is 1.67.


Solvonis Therapeutics Beta Historical Data

The historical data trend for Solvonis Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solvonis Therapeutics Beta Chart

Solvonis Therapeutics Annual Data
Trend May18 May19 May20 May21 Dec22 Dec23
Beta
Get a 7-Day Free Trial - - - - -

Solvonis Therapeutics Semi-Annual Data
May18 May19 May20 May21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Solvonis Therapeutics's Beta

For the Specialty Industrial Machinery subindustry, Solvonis Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solvonis Therapeutics's Beta Distribution in the Industrial Products Industry

For the Industrial Products industry and Industrials sector, Solvonis Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Solvonis Therapeutics's Beta falls into.



Solvonis Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Solvonis Therapeutics  (LSE:SVNS) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Solvonis Therapeutics Beta Related Terms

Thank you for viewing the detailed overview of Solvonis Therapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Solvonis Therapeutics Business Description

Traded in Other Exchanges
Address
Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

Solvonis Therapeutics Headlines

No Headlines